Amgen’s Tepezza granted marketing authorisation in the UK

8th May 2025 Uncategorised 0

Teprotumumab approved as first targeted treatment for thyroid eye disease

More: Amgen’s Tepezza granted marketing authorisation in the UK
Source: News